GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Brawn Biotech Ltd (BOM:530207) » Definitions » Cyclically Adjusted Revenue per Share

Brawn Biotech (BOM:530207) Cyclically Adjusted Revenue per Share : ₹170.28 (As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Brawn Biotech Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Brawn Biotech's adjusted revenue per share for the three months ended in Dec. 2024 was ₹12.820. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹170.28 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Brawn Biotech's average Cyclically Adjusted Revenue Growth Rate was -6.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Brawn Biotech was 0.20% per year. The lowest was 0.20% per year. And the median was 0.20% per year.

As of today (2025-05-31), Brawn Biotech's current stock price is ₹17.10. Brawn Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 was ₹170.28. Brawn Biotech's Cyclically Adjusted PS Ratio of today is 0.10.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Brawn Biotech was 0.24. The lowest was 0.08. And the median was 0.11.


Brawn Biotech Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Brawn Biotech's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Brawn Biotech Cyclically Adjusted Revenue per Share Chart

Brawn Biotech Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 176.08 179.09 183.98 177.30

Brawn Biotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 181.73 177.30 177.74 174.77 170.28

Competitive Comparison of Brawn Biotech's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Brawn Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brawn Biotech's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Brawn Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Brawn Biotech's Cyclically Adjusted PS Ratio falls into.


;
;

Brawn Biotech Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Brawn Biotech's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=12.82/158.3229*158.3229
=12.820

Current CPI (Dec. 2024) = 158.3229.

Brawn Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 27.669 97.163 45.085
201506 32.492 99.841 51.524
201509 41.400 101.753 64.416
201512 42.490 102.901 65.375
201603 38.675 102.518 59.727
201606 49.375 105.961 73.774
201609 43.312 105.961 64.715
201612 54.391 105.196 81.860
201703 54.678 105.196 82.292
201706 36.478 107.109 53.920
201709 38.651 109.021 56.130
201712 50.099 109.404 72.500
201803 52.350 109.786 75.494
201806 49.823 111.317 70.862
201809 49.864 115.142 68.564
201812 70.779 115.142 97.323
201903 51.233 118.202 68.623
201906 59.492 120.880 77.920
201909 39.598 123.175 50.897
201912 44.076 126.235 55.280
202003 22.094 124.705 28.050
202006 24.774 127.000 30.884
202009 32.332 130.118 39.340
202012 49.274 130.889 59.602
202103 10.156 131.771 12.202
202106 3.760 134.084 4.440
202109 6.926 135.847 8.072
202112 8.426 138.161 9.656
202203 7.401 138.822 8.441
202206 11.151 142.347 12.402
202209 25.890 144.661 28.335
202212 21.030 145.763 22.842
202303 10.652 146.865 11.483
202306 24.518 150.280 25.830
202309 9.874 151.492 10.319
202312 9.454 152.924 9.788
202403 8.190 153.035 8.473
202406 14.082 155.789 14.311
202409 9.209 157.882 9.235
202412 12.820 158.323 12.820

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Brawn Biotech  (BOM:530207) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Brawn Biotech's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=17.10/170.28
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Brawn Biotech was 0.24. The lowest was 0.08. And the median was 0.11.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Brawn Biotech Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Brawn Biotech's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Brawn Biotech Business Description

Industry
Traded in Other Exchanges
N/A
Address
Plot No. 30, Sector 33, Near Hero Honda Factory, Gurugram, HR, IND, 122001
Brawn Biotech Ltd is a healthcare company. It is primarily engaged in the business activity of wholesale of pharmaceutical and medical goods. The company's pharmaceutical goods cover product segments like Antibacterial, Cardiovascular, Anti-diabetic, Analgesics, Gastrointestinal, Antifungals, Skin Care, Antipsychotics, Anti-asthmatic, Antacids, Antimalarial, and Nutritionals. It markets pharmaceutical products in India and internationally. The company generates a major portion of its revenue from exports.

Brawn Biotech Headlines

No Headlines